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Abstract
Objective: Cross-sectional genetic association studies have reported equivocal results on the relationship between the
brain-derived neurotrophic factor (BDNF) Val66Met and risk of Alzheimer’s disease (AD). As AD is a neurodegenerative
disease, genetic influences may become clearer from prospective study. We aimed to determine whether BDNF Val66Met
polymorphism influences changes in memory performance, hippocampal volume, and Ab accumulation in adults with
amnestic mild cognitive impairment (aMCI) and high Ab.
Methods: Thirty-four adults with aMCI were recruited from the Australian, Imaging, Biomarkers and Lifestyle (AIBL) Study.
Participants underwent PiB-PET and structural MRI neuroimaging, neuropsychological assessments and BDNF genotyping at
baseline, 18 month, and 36 month assessments.
Results: In individuals with aMCI and high Ab, Met carriers showed significant and large decline in episodic memory
(d = 0.90, p = .020) and hippocampal volume (d = 0.98, p = .035). BDNF Val66Met was unrelated to the rate of Ab
accumulation (d = 20.35, p = .401).
Conclusions: Although preliminary due to the small sample size, results of this study suggest that high Ab levels and Met
carriage may be useful prognostic markers of accelerated decline in episodic memory, and reductions in hippocampal
volume in individuals in the prodromal or MCI stage of AD.
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assessment at baseline, 18 and 36 month follow-up (Table 1).
The process of recruitment and diagnostic classification of adults
with aMCI enrolled in the AIBL cohort has been described in
detail previously [15]. Participants who volunteered were excluded
from the AIBL study if they had any of the following:
schizophrenia; depression (Geriatric Depression Score (GDS) of
6 or greater); Parkinson’s disease; cancer (other than basal cell skin
carcinoma) within the last two years; symptomatic stroke;
uncontrolled diabetes; or current regular alcohol use exceeding
two standard drinks per day for women or four per day for men. A
clinical review panel chaired by DA reviewed all available medical,
psychiatric and neuropsychological information to ensure that
their clinical classification was consistent with international criteria
[16,17]. Clinical classification was blinded to Ab imaging data.
The AIBL study was approved by the institutional ethics
committees of Austin Health, St Vincent’s Health, Hollywood
Private Hospital and Edith Cowan University [15]. All participants with MCI and their caregivers provided written informed
consent prior to being tested.

Introduction
Current models of Alzheimer’s disease (AD) emphasise betaamyloid (Ab) as precipitating a cascade of events that result in
synaptic loss and memory impairment [1]. Recent in vitro evidence
suggests neurotrophic factors such as brain-derived neurotrophic
factor (BDNF) may be an indirect moderator of Ab neurotoxicity,
as BDNF and its main receptor, tropomyosin-related kinase B
(TrkB) are not involved in amyloidogenesis, but rather in synaptic
excitation and neuronal plasticity, which may provide an ability
for the central nervous system (CNS) to withstand Ab-related
neuronal death [224]. Further, in individuals with AD or mild
cognitive impairment (MCI), BDNF messenger ribonucleic acid
(mRNA) is reduced substantially in the hippocampus and temporal
lobe, with the extent of BDNF loss associated with the magnitude
of cognitive impairment [5,6]. Unfortunately, there are currently
no validated peripheral markers of central nervous system (CNS)
BDNF [3,4]. Therefore, in humans, conclusions about the role of
BDNF in AD have been based on the measurement of the effect of
BDNF polymorphisms (e.g., Val66Met [rs6265]) on clinical or
pathological features of the disease, or on risk for AD [3,4].
Unfortunately, evidence from such studies has been mixed with
some showing BDNFMet carriers to have increased memory
impairment, brain atrophy or risk of AD while others show that
these same impairments are associated with BDNFVal homozygosity [3,4,7].
We [8] and others [3] have argued that the inconsistency of
relationships between the BNDF Val66Met polymorphism and AD
in human studies suggest the involvement of a moderating factor.
As a proportion of healthy individuals at risk for AD have high Ab
[9,10], and healthy individuals with high Ab show substantial
decline in episodic memory as well as increased hippocampal
atrophy [10212]_ENREF_5, the effects of BDNF polymorphisms
may be moderated by Ab levels. Recently, we observed an
epistatic relationship between the BDNF Val66Met polymorphism
and Ab deposition in which BDNFMet healthy individuals showed a
faster rate of hippocampal atrophy and episodic memory decline
than BDNFVal homozygotes, but only if they had abnormally high
Ab [8]. Thus, this suggests that Ab deposition may moderate the
relationship between the BDNF Val66Met polymorphism and risk
of AD.
Objective but subtle memory impairment with corroborating
evidence of memory difficulties from a reliable informant is
codified as the clinical classification mild cognitive impairment
(MCI), and is associated with increased risk of progression to AD
[12214]. This risk is increased if the MCI classification is
accompanied by the presence of abnormal Ab levels [14].
Therefore, another test of the hypothesis that the BDNF Val66Met
polymorphism increase risk of AD would be if individuals with
MCI and high Ab who are BDNFMet carriers show greater decline
in episodic memory and hippocampal volume than BDNFVal
homozygotes. However, as BDNF is an indirect mediator of Ab
toxicity, a second hypothesis is that the BDNF Val66Met
polymorphism will not affect Ab accumulation.

Measures
Neuroimaging. PiB-PET imaging was conducted as described previously [9,10]. PET standardized uptake value (SUV)
data acquired 40-70 minutes post-PiB injection were summed and
normalized to the cerebellar cortex SUV, resulting in a region-tocerebellar ratio termed SUV ratio (SUVR).
Magnetic resonance (MR) images were spatially normalized to
the Montreal Neurological Institute (MNI) single-subject MRI
brain template, [18] using MilxViewH, software developed by the
Australian e-Health Research Centre – BioMedIA (Brisbane,
Australia). As described elsewhere, T1W MR images for each
subject were classified into grey matter (GM), white matter (WM)
and CSF using an implementation of the expectation maximization segmentation algorithm[19]. The algorithm computed
probability maps for each tissue type and was used to assign each
voxel to its most likely tissue type and subsequent segmentation.
To improve the accuracy of analysis of the hippocampus, a
separate, manually-delineated template was drawn on the MNI
single-subject every 1 mm on coronal slices, and was subsequently
used for hippocampal volume. The average hippocampal volumes
were normalized for head size using the total intracranial volume,
defined as the sum of GM, WM and CSF volumes.
Genotyping. An 80 ml blood sample was taken from each
participant and 10 ml was used for large scale DNA extraction for
AIBL bio-banking. The BDNF Val66Met polymorphism (rs6265)
was included in a custom Illumina GoldenGate assay, which
included 1536 SNPs, and was performed by the Beijing Genomics
Institute. Val66Met polymorphism had a call rate of greater than
99% and did not depart from Hardy-Weinberg equilibrium in the
AIBL aMCI group.
Clinical and cognitive assessments. The AIBL clinical
and cognitive battery has been described in detail elsewhere and
were administered according to standard protocols by trained
research assistants [15], although the current study focused only
on data for episodic memory. Clinical status was determined using
information which included the Mini-Mental Status Examination
(MMSE) and Clinical Dementia Rating (CDR) Scale. Premorbid
intelligence was estimated using the Wechsler Test of Adult
Reading (WTAR), and depressive and anxiety symptoms were
assessed using the Hospital Anxiety and Depression Scale (HADS).

Methods
Participants
Thirty-four adults with aMCI and high Ab levels enrolled in the
Australian Imaging, Biomarkers and Lifestyle (AIBL) Study were
included in this study [9,15]. Participants had undergone BDNF
genotyping at baseline, and positron emission tomography (PET)
neuroimaging using Pittsburgh Compound B (PiB), structural
magnetic resonance imaging (MRI), and neuropsychological
PLOS ONE | www.plosone.org
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Table 1. Demographic means (SD) for MMSE, CDR-SB, premorbid IQ and HADS scores, and median years of education, for overall
and each BDNF group at baseline assessment.

Overall (n = 34)

BDNFVal homozygote (n = 24)

BDNFMet carrier (n = 10)

N (%) female

17 (50%)

12 (50%)

5 (50%)

1.00

N (%) APOE e4

28 (82%)

19 (79%)

9 (90%)

.450

Age (years)

76.41 (6.36)

75.33 (5.47)

79.00 (7.83)

.127

SUVR Neocortex

2.22 (0.41)

2.14 (0.36)

2.39 (0.49)

.113

MMSE

27.03 (1.90)

27.08 (1.77)

26.90 (2.28)

.802

CDR-SB

1.03 (0.75)

1.04 (0.82)

1.00 (0.56)

.890

p

Premorbid IQ

109.09 (7.03)

107.63 (7.32)

112.60 (4.97)

.059

HADS-Depression

3.50 (2.44)

3.54 (2.60)

3.40 (2.12)

.880

HADS-Anxiety

4.82 (2.52)

4.71 (2.56)

5.10 (2.51)

.113

Note: One-Way ANOVA indicated no significant differences between Val/Val homozygotes and Met carriers on any demographic or clinical characteristic, p’s ,.05. x2
indicated that number of APOE e4 carriers, p = .45, and number of females, p = 1.00, were not higher in Met carriers.
Standardized Uptake Value Ratio; MMSE = Mini-Mental State Examination; CDR-SB = Clinical Dementia Rating Scale, Sum of Boxes Score; HADS-Depression = Hospital
Anxiety and Depression Scale, Depression Subscale; HADS-Anxiety = Hospital Anxiety and Depression Scale, Anxiety Subscale.
doi:10.1371/journal.pone.0086498.t001

in magnitude. While increased memory decline and hippocampal
atrophy have been reported previously in adults with aMCI and
high Ab [10212], results of the current study suggests a direct link
between Ab and the BDNF Val66Met polymorphism on
progressive memory decline and hippocampal atrophy in prodromal AD.
The second hypothesis that the BDNF Val66Met polymorphism
would not moderate the rate of Ab accumulation in adults with
aMCI and high Ab was also supported. While Ab levels increased
for both BDNFMet carriers and BDNFVal homozygotes over 36
months, the rate of Ab accumulation across 36 months was not
different between groups (Figure 1c). Thus, while high baseline Ab
was associated with memory decline and hippocampal atrophy,
the deleterious effects were reduced in individuals who carried the
BDNF Val66Met polymorphism that has been associated with
greater secretion of the BDNF protein (i.e., BDNFVal homozygotes).
The results of this study are consistent with our previous finding
in healthy individuals, where BDNFMet carriers with high Ab
showed significantly higher rates of episodic memory decline and
hippocampal atrophy than BDNFVal homozygotes, despite no
differences in the rates of Ab accumulation [8]. Further, these
results are consistent with animal studies, which have shown that
the secretion of mature BDNF is crucial in the neuronal integrity
of the hippocampus [2,20], and that Ab decreases BDNF levels by
reducing phosphorylated cAMP response element binding protein,
which in turn regulates BDNF transcript expression [5]. Human
and animal neuropathological studies have also found that
interactions between BDNF Val66Met and Ab-related synaptic
changes occur in the hippocampus, and that these changes are
related directly to memory [2,20,21]. Finally, genetic databases do
not identify BDNF Val66Met polymorphism as increasing risk for
AD [22]. Taken together, these data suggest that while BDNF
Val66Met is unrelated to the presence of Ab or to its
accumulation, it may moderate the extent to which Ab affects
brain structure and memory function, at least in the prodromal
stages of AD.
An important caveat of the current study is that the AIBL study
is not an epidemiological sample. The selection of MCI groups
was biased towards the inclusion of individuals with aMCI, and
participants were predominantly highly educated, and had few
existing or untreated medical or psychiatric illnesses. As such, it

delayed recall, California Verbal Learning Test, Second Edition
[CVLT-II] delayed recall) against the baseline mean and SD for
the entire group and then averaging them. As in previous studies
[9,10], adults with aMCI were classified as having high Ab if they
had an SUVR$1.5. Linear mixed model (LMM) analyses of
covariance were conducted to compare linear slopes of change in
episodic memory, hippocampal volume and SUVR between
BDNF groups across baseline, 18 and 36 month assessments.
Linear mixed modelling was employed because of its ability to
model both fixed and random effects, which accounts for multiple
sources of variability, and because it provides improved estimates
of within-subject coefficients (i.e., random effects) in longitudinal
studies. For each LMM, BDNF, time, and BDNF-time interaction
were entered as fixed factors; participant as a random factor; age
and APOE status as covariates; and episodic memory, hippocampal volume or Ab accumulation as dependent variables. For each
outcome, the magnitude of the difference in slopes between the
BDNF Val66Met polymorphism groups was expressed using
Cohen’s d.

Results
Demographic and clinical characteristics of the total sample and
BDNF Val66Met polymorphism groups are shown in Table 1.
Study groups were matched on all demographic and clinical
characteristics.
Relative to BDNFVal homozygotes, BDNFMet carriers showed a
greater rate of decline in episodic memory and reduction in
hippocampal volume over 36 months (Table 2, Figure 1a, 1b),
with the effect size of difference between slopes for both measures,
large in magnitude. Groups did not differ in the rate of Ab
accumulation over 36 months (Table 2, Figure 1c).

Discussion
The first hypothesis that the BDNF Val66Met polymorphism
would moderate memory decline and hippocampal atrophy in
aMCI with high Ab was supported. In adults with aMCI for whom
PiB-PET neuroimaging indicated high baseline Ab, BDNFMet
carriers showed greater episodic memory decline and hippocampal atrophy over 36 months compared to BDNFVal homozygotes,
and the rate of decline between groups was, by convention, large
PLOS ONE | www.plosone.org
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Figure 1. Trajectories of change in Episodic Memory Composite (1a), Hippocampal volume atrophy (1b), and Ab accumulation (1c)
for Val homozygotes and Met carriers (error bars represent 95% confidence intervals).
doi:10.1371/journal.pone.0086498.g001

and the previous observation that APOE e4 does not interact with
BDNF levels to affect cognitive function [23]. However, further
investigation of the relationship between APOE, BDNF Val66Met,
and Ab on change in cognition needs to be conducted in larger,
prospective studies of APOE allele groups [24,25]. Finally, due to
small sample sizes, we were unable to investigate whether
BDNFVal66Met polymorphism has an effect on cognitive decline
in individuals with MCI and low Ab. However, as individuals with
MCI and low Ab do not show memory decline over 18 or 36

would be important for these findings to be replicated in adults
with MCI and high Ab in population-based studies, such as the
Mayo Clinic Study of Aging, where it is possible that the effect of
the BDNF Val66Met polymorphism on Ab-related decline may be
greater than that observed here. A second caveat is that we only
investigated indirect interactions between APOE, BDNF Val66Met,
Ab and cognitive decline in adults with aMCI. This was primarily
due to the small sample size, equivalence in the proportion of
APOE e4 carriers in BDNFMet carriers and BDNFVal homozygotes,

Table 2. Mean slopes (SD) for each neuropsychological measure, and magnitude of difference (Cohen’s d) in slopes.

Episodic Memory

Hippocampal Atrophy

Ab accumulation

(df) F

p

(df) F

P

(df) F

p

Age

(1,34) 0.312

.580

(1,32) 1.042

.315

(1,35) 4.538

.040

APOE

(1,33) 1.242

.273

(1,31) 2.951

.096

(1,33) 1.437

.239

Time

(1,24) 36.07

.000

(1,17) 166.041

.000

(1,20) 82.358

.000

BDNF

(1,28) 0.756

.392

(1,32) 5.412

.026

(1,34) 0.997

.325

BDNF x Time

(1,24) 6.228

.020

(1,17) 5.241

.035

(1,20) 0.735

.401

Val

Mean slope (SD)

Mean slope (SD)

20.189 (0.310)

20.128 (0.057)

0.079 (0.049)

Ab+ BDNFMet carrier (n = 10)

20.457 (0.270)

20.184 (0.057)

0.096 (0.046)

Cohen’s d (95%CI)

0.90 (0.11, 1.64)

0.98 (0.19, 1.73)

20.35 (21.09, 0.40)

Ab+ BDNF

homozygote (n = 24)

Mean slope (SD)

doi:10.1371/journal.pone.0086498.t002
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months [12,14], and as we have previously shown that in healthy
older adults, BDNFVal66Met polymorphism only exerts its effects
on cognitive function and brain structure in individuals with high
Ab [8], we hypothesize that the BDNFVal66Met polymorphism
would not have an effect on cognitive function and hippocampal
volume in individuals with MCI and low Ab.
Notwithstanding this limitation, results of the current study
provide preliminary support for high Ab and BDNF Val66Met
polymorphism as important prognostic markers of increased
memory decline and hippocampal atrophy in individuals with
prodromal AD [13]. Further, as pharmacologically increasing
BDNF levels in AD mouse models can ameliorate synaptic
dysfunction and improve memory [26], and increasing BDNF
secretion through aerobic exercise have been shown to improve
memory performance in humans at risk for AD [27], interventions
geared toward increasing BDNF levels may be a potential
therapeutic strategy for the early stages of AD.
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